Home|Journals|Articles by Year|Audio Abstracts
 

Case Report

Open Vet J. 2022; 12(5): 762-767


Effective treatment with mitotane for a canine case of Ectopic Cushing's syndrome-related pheochromocytoma.

Konatsu Miura,Hiroshi Sunahara,Yusuke Sakai.




Abstract
Cited by 0 Articles

In humans, ectopic Cushing’s syndrome (ECS) is characterized by hypercortisolemia, which
is caused by small lung carcinoma, bronchial carcinoids, and pheochromocytoma. In dogs, only a few cases of ECS associated with pheochromocytoma has been reported to date. Herein, we describe a canine case of malignant pheochromocytoma that presumed to be the cause of ECS. An 11-year-old, castrated, male Toy Poodle with hypercortisolemia was diagnosed as adrenal tumor and treated with mitotane. Although repeated adrenocorticotropic hormone stimulation tests revealed improvement of the dog’s condition by mitotane treatment, its condition started declining from 197 days post-diagnosis, and he died on day 280. The
necropsy revealed the adrenal tumor was pheochromocytoma, not adrenocortical tumor. However, because of no pathological change in pituitary gland and the other adrenal gland, the pheochromocytoma was presumed to be the cause of ECS. This is the first report that describe the effectiveness of mitotane against presumed ECS-related pheochromocytoma.

Key words: dog, ectopic Cushing’s syndrome, hypercortisolemia, pheochromocytoma.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.